| Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes S De Talhouet, J Peron, A Vuilleumier, A Friedlaender, V Viassolo, ... Scientific reports 10 (1), 7073, 2020 | 133 | 2020 |
| Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer SI Labidi-Galy, T Olivier, M Rodrigues, D Ferraioli, O Derbel, A Bodmer, ... Clinical Cancer Research 24 (2), 326-333, 2018 | 56 | 2018 |
| Exome sequencing and pathogenicity-network analysis of five French families implicate mTOR signalling and autophagy in familial sarcoidosis A Calender, CX Lim, T Weichhart, A Buisson, V Besnard, ... European Respiratory Journal 54 (2), 2019 | 48 | 2019 |
| Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: a powerful approach SM Caputo, L Golmard, M Léone, F Damiola, M Guillaud-Bataille, ... The American Journal of Human Genetics 108 (10), 1907-1923, 2021 | 32 | 2021 |
| Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers SI Labidi-Galy, TLM Rouge, O Derbel, A Wolfer, E Kalbacher, T Olivier, ... Gynecologic oncology 155 (2), 262-269, 2019 | 30 | 2019 |
| Whole exome sequencing in three families segregating a pediatric case of sarcoidosis A Calender, PA Rollat Farnier, A Buisson, S Pinson, A Bentaher, ... BMC medical genomics 11, 1-19, 2018 | 28 | 2018 |
| Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer R Cohen, V Jonchère, C De La Fouchardière, T Ratovomanana, ... Journal for Immunotherapy of Cancer 9 (2), 2021 | 27 | 2021 |
| BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients A Friedlaender, A Vuilleumier, V Viassolo, A Ayme, S De Talhouet, ... Breast cancer research and treatment 174, 775-783, 2019 | 22 | 2019 |
| 201 Homologous recombination deficiency testing in advanced ovarian cancer: description of the ENGOT HRD European initiative E Pujade-Lauraine, Y Christinat, M D’incalci, P Schouten, A Buisson, ... International Journal of Gynecologic Cancer 31 (Suppl 3), 2021 | 18 | 2021 |
| Attempting to solve the pigmented epithelioid melanocytoma (PEM) conundrum: PRKAR1A inactivation can occur in different genetic backgrounds (common, blue, and Spitz subgroups … A de La Fouchardiere, F Tirode, C Castillo, A Buisson, F Boivin, ... The American Journal of Surgical Pathology 46 (8), 1106-1115, 2022 | 14 | 2022 |
| Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe P Hofman, F Calabrese, I Kern, J Adam, A Alarcão, I Alborelli, NT Anton, ... ESMO open 8 (5), 101628, 2023 | 13 | 2023 |
| Alterations in homologous recombination-related genes and distinct platinum response in metastatic triple-negative breast cancers: a subgroup analysis of the ProfiLER-01 trial E Bonnet, V Haddad, S Quesada, KA Baffert, A Lardy-Cléaud, I Treilleux, ... Journal of Personalized Medicine 12 (10), 1595, 2022 | 10 | 2022 |
| The intronic BRCA1 c.5407-25T>A variant causing partly skipping of exon 23—a likely pathogenic variant with reduced penetrance? H Høberg-Vetti, E Ognedal, A Buisson, TBA Vamre, S Ariansen, ... European Journal of Human Genetics 28 (8), 1078-1086, 2020 | 10 | 2020 |
| Response to the combination of osimertinib, dabrafenib, and trametinib in leptomeningitis from EGFR-mutant NSCLC with acquired BRAF V600E mutation: a case report O Valet, A Swalduz, M Boussageon, A Buisson, V Avrillon, B Mastroïanni, ... JTO Clinical and Research Reports 2 (6), 100192, 2021 | 8 | 2021 |
| Compound blue nevus: a reappraisal of the concept in the genomic era J Jaquemus, E Perron, A Buisson, G Ferrara, V Haddad, ... Virchows Archiv 476 (3), 439-443, 2020 | 8 | 2020 |
| Supravalvular aortic stenosis caused by a familial chromosome 7 inversion disrupting the ELN gene uncovered by whole-genome sequencing L Pons, P Bouvagnet, M Bakloul, S Di Filippo, A Buisson, N Chatron, ... Molecular Syndromology 10 (4), 209-213, 2019 | 8 | 2019 |
| A deep learning solution for detection of homologous recombination deficiency in ovarian cancer using low pass whole-genome sequencing: Evaluation of the analytical performance. A Buisson, P Saintigny, E Pujade-Lauraine, C Montoto-Grillot, D Vacirca, ... Journal of Clinical Oncology 40 (16_suppl), e17599-e17599, 2022 | 7 | 2022 |
| GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles C Pozzorini, G Andre, T Coletta, A Buisson, J Bieler, L Ferrer, R Kempfer, ... Cell Reports Medicine 4 (12), 2023 | 6 | 2023 |
| 2022-RA-913-ESGO Clinical performance evaluation of a novel deep learning solution for homologous recombination deficiency detection A Buisson, P Saintigny, A Harle, D Vacirca, M Barberis, P Gilson, C Roma, ... International Journal of Gynecologic Cancer 32 (Suppl 2), 2022 | 6 | 2022 |
| Overview of the genetic causes of hereditary breast and ovarian cancer syndrome in a large French patient cohort A Bouras, S Guidara, M Leone, A Buisson, T Martin-Denavit, S Dussart, ... Cancers 15 (13), 3420, 2023 | 4 | 2023 |
